Optimization of a protocol for the evaluation of antibody responses to human papillomavirus (HPV) vaccination in low-resource settings
| dc.contributor.author | Donkoh Timmy Emmanuel | |
| dc.contributor.author | Dassah Tieru Edward | |
| dc.contributor.author | Owusu-Dabo Ellis | |
| dc.date.accessioned | 2023-12-11T16:05:33Z | |
| dc.date.available | 2023-12-11T16:05:33Z | |
| dc.date.issued | 2022 | |
| dc.description | This article is published by BioMed Central and is also available at https://doi.org/10.1186/s12905-022-01821-y | |
| dc.description.abstract | Introduction: Available human papillomavirus (HPV) vaccines could have an important primary role in cervical can‑ cer prevention once their long-term immunogenicity and safety are evaluated at the population level. The aim of this study was to optimize an assay to be used in evaluating the long-term durability of HPV vaccine response following a pilot vaccination of adolescent girls in Ghana. Methods: A rapid, high-throughput, indirect enzyme-linked immunosorbent assay (ELISA) was optimized for the detection and quantitation of anti-HPV L1 (late expression protein: types 6, 11, 16 and 18) immunoglobulin G (IgG) in human serum (n=89). The utility of the assay was demonstrated using serum collected from a cohort of pre adolescent girls (n=49) previously vaccinated with a quadrivalent vaccine and non-immune serum obtained from age-matched controls (n=40). Results: The assay showed good discrimination of antibody levels between cases and control sera: seroprevalence of anti-HPV IgG antibodies was signifcantly higher among vaccinated than unvaccinated girls for both HPV-16 (63.3% vs. 12.5%; p<0.001) and HPV-18 (34.7% vs. 20.0%; p=0.042), respectively. Thirty-six months after receiving the third dose of vaccine, signifcantly higher mean anti-HPV-16 (0.618 vs. 0.145), anti-HPV-18 (0.323 vs. 0.309), and anti-HPV-6 (1.371 vs. 0.981) antibody levels were measured, compared to unvaccinated girls (all p<0.05). A correlation between optical density and antibody activity indicated assay sensitivity to increasing levels of antibody activity. Conclusion: We have successfully optimized and implemented a robust and sensitive assay for the evaluation of antibody responses among immunized adolescent girls for monitoring future large-scale HPV vaccination studies in low-income settings. Our results demonstrated greater immunoglobulin G antibody activity within serum drawn from adolescent girls immunized 36 months prior. | |
| dc.description.sponsorship | KNUST | |
| dc.identifier.citation | Donkoh et al. BMC Women’s Health (2022) 22:234 https://doi.org/10.1186/s12905-022-01821-y | |
| dc.identifier.uri | 10.1186/s12905-022-01821-y | |
| dc.identifier.uri | https://ir.knust.edu.gh/handle/123456789/14777 | |
| dc.language.iso | en | |
| dc.publisher | BioMed Central | |
| dc.title | Optimization of a protocol for the evaluation of antibody responses to human papillomavirus (HPV) vaccination in low-resource settings | |
| dc.type | Article |